Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by New York University School of Medicine
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
First received: June 11, 2013
Last updated: April 1, 2016
Last verified: April 2016
The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This is a "phase 0" PK (pharmacokinetic) and PD (pharmacodynamic) study of RAD001 in patients with Neurofibromatosis Type 2-related and sporadic VS and meningiomas. Enrolled patients will take RAD001 prior to a scheduled VS or meningioma surgery, and blood and tissue samples will be obtained for further analysis.

Condition Intervention Phase
Neurofibromatosis Type 2
Vestibular Schwannomas
Drug: RAD001
Phase 0

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

Resource links provided by NLM:

Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • Proportions of VS and meningiomas after exposure to RAD001 [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    1) To estimate the proportions of VS and meningiomas with complete inhibition of phospho-S6 after10 days of exposure to RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This endpoint was chosen based on prior pharmacodynamic data from a published trial, showing complete inhibition of phospho-S6 in solid tumor tissue of patients treated with RAD001 and our own preliminary data confirming baseline phospho-S6 expression in VS and meningiomas.

Estimated Enrollment: 51
Study Start Date: June 2013
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RAD001
RAD001 taken by mouth 10mg daily for 10 days before surgery
Drug: RAD001
Other Name: Everolimus


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must satisfy all of the following eligibility criteria:
  • Karnofsky performance status (KPS) ≥ 60%
  • Absolute neutrophil count ≥ 1,000/mm³ (unsupported)
  • Platelet count ≥ 100,000/mm³ (unsupported)
  • Hemoglobin ≥ 8 g/dl (transfusion support allowed)
  • Creatinine ≤ 1.5 times upper limit of normal (ULN*) OR corrected glomerular filtration rate ≥ 70 ml/min
  • Total bilirubin ≤ 1.5 times ULN*
  • ALT ≤ 2.5 times ULN*
  • Serum albumin ≥ 2 g/dl
  • INR < 1.3 (or < 3 on anticoagulants)
  • Patients taking a cholesterol-lowering agent must be on a single medication and on a stable dose for at least 4 weeks
  • Fasting serum cholesterol ≤ 300 mg/dl OR ≤ 7.75 mmol/l AND fasting triglycerides ≤ 2.5 times ULN*.
  • Fully recovered from acute toxic effects of any prior chemotherapy, biological modifiers or radiotherapy
  • Any neurologic deficits must be stable for ≥ 1 week
  • Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test. The anti-proliferative activity of this experimental drug may be harmful to the developing fetus.
  • Able to provide written informed consent

Exclusion Criteria:

  • Patients with any of the following are ineligible for this research study:
  • Patients with VS or meningiomas deemed very high surgical risk for stroke and/or other complications by the attending surgeon, such as meningiomas with major vascular or dural sinus infiltration.
  • Patients with serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety.
  • Symptomatic congestive heart failure or unstable angina pectoris.
  • Uncontrolled diabetes, as defined by fasting serum glucose >1.5 times ULN*.
  • Current active hepatic or biliary disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis (with exception of patients with Gilbert's syndrome and asymptomatic gallstones).
  • History of hepatitis B or C. Note: A detailed assessment of hepatitis B/C medical history and risk factors must be done at screening for all patients. HBV serology, DNA and/or HCV RNA PCR testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection. If no positive medical history for risk factors, serology is not required.
  • Seropositivity or DNA/RNA positivity for hepatitis B or C, with the exception of patients who have received prior Hepatitis B vaccination and are Anti-HBs positive only.
  • Known HIV seropositivity
  • Neurologic deficits that are rapidly progressing: all neurologic signs and symptoms must have been stable for a week prior to first dose
  • Patients who are pregnant or breast-feeding. The anti-proliferative activity of this experimental drug may be harmful to the developing fetus or nursing infant.
  • Anti-tumor therapy (i.e. chemotherapeutics or investigational agents or immunotherapy) within 4 weeks prior to enrollment
  • Radiation therapy to a study target lesion within 6 months
  • Prior therapy with mTOR inhibitors, including sirolimus, temsirolimus, deforolimus within 6 months prior to enrollment
  • Known hypersensitivity to RAD001 or other rapamycins (sirolimus, temsirolimus, deforolimus)
  • Patients with a concurrent malignancy
  • Patients treatment with systemic steroids or another immunosuppressive agent. Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary.
  • Patients cannot receive CYP3A4 inhibiting drugs including antibiotics (clarithromycin, erythromycin, troleandomycin), anti-HIV agents (delaviridine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, lopinavir), antifungals (itraconazole, ketoconazole, fluconazole at doses > 200 mg/day, voriconazole), antidepressants (nefazodone, fluovoxamine), calcium channel blockers (verapamil, diltiazem) oramiodarone
  • Patients should avoid CYP3A4 inhibiting foods including grapefruit and Seville orange juice.
  • Patients cannot receive CYP3A4 inducing anticonvulsants including carbamazepine, felbamate, phenobarbital, phenytoin, primidone and oxcarbazepine, or other CYP3A4 inducers such as St. John's Wort
  • Patients who previously received CYP3A4 inducers or inhibitors must have discontinued these medications within at least 1 week prior to study entry and can re-start them 1 week post-operatively (or earlier if determined to be of clinical benefit, as determined by the treating physician).

    • of institutional norms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01880749

Contact: Matthias A Karajannis, MD 212-263-8400 matthias.karajannis@nyumc.org
Contact: Carole W Mitchell, RN 212-263-8400 carole.mitchell@nyumc.org

United States, New York
New York University School of Medicine Recruiting
New York, New York, United States, 10016
Contact: Matthias A. Karajannis, MD    212-263-8400    matthias.karajannis@nyumc.org   
Principal Investigator: Matthias A Karajannis, MD, MS         
Sponsors and Collaborators
New York University School of Medicine
Study Chair: Matthias A Karajannis, MD New York University School of Medicine
  More Information

Responsible Party: New York University School of Medicine
ClinicalTrials.gov Identifier: NCT01880749     History of Changes
Other Study ID Numbers: S12-02808, CRAD001CUS205T 
Study First Received: June 11, 2013
Last Updated: April 1, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Neurofibromatosis 2
Neuroma, Acoustic
Central Nervous System Neoplasms
Cranial Nerve Diseases
Cranial Nerve Neoplasms
Ear Diseases
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Meningeal Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neoplasms, Vascular Tissue
Neoplastic Syndromes, Hereditary
Nerve Sheath Neoplasms
Nervous System Diseases
Nervous System Neoplasms
Neurocutaneous Syndromes
Neurodegenerative Diseases
Neuroectodermal Tumors
Neuroendocrine Tumors
Neuromuscular Diseases
Otorhinolaryngologic Diseases

ClinicalTrials.gov processed this record on May 26, 2016